Publications by authors named "Nagore Garcia Exposito"
Prostate-specific Antigen at 3 Months as a Predictor of Radiologic Progression-free Survival in Metastatic Hormone-sensitive Prostate Cancer Treated with Apalutamide: Analysis of 633 Patients in a Real-world Database.
Eur Urol Open Sci
December 2024
Background And Objective: The depth of the prostate-specific antigen (PSA) decline after androgen receptor pathway inhibitor (ARPI) treatment combined with androgen deprivation therapy for patients with metastatic hormone-sensitive prostate cancer (mHSPC) may affect prognosis. The primary objective in our study was the correlation between the PSA response at 3 mo and radiologic progression-free survival (rPFS) at 24 mo. Three groups were defined according to the PSA decline: complete response (PSA ≤0.
View Article and Find Full Text PDFArticle Synopsis
- This study evaluated the outcomes of 44 patients with recurrent glioblastoma who underwent reirradiation after an initial treatment, finding that median overall survival after the second treatment was 14.9 months.
- The most common reirradiation method used was 35 Gy in 10 fractions, with mild acute side effects and a 40% rate of radiological response; however, many patients also experienced early distant progressions.
- Factors like a Karnofsky index below 70 and smaller recurrence sizes were linked to better overall survival, suggesting reirradiation is a viable option, especially for patients in good health with smaller lesions.
Background: Surgery and stereotactic body radiotherapy (SBRT) are two of the options available as local treatments for pulmonary oligometastases from colorectal cancer (CRC). We hypothesized that SBRT would have, at least, a similar local control rate to surgery.
Methods: We identified an initial cohort of 100 patients with CRC who received SBRT or surgery for lung metastases.